



PRESS RELEASE

DE SANGOSSE GROUP IS EVALUATING AMOEBA'S BIOCONTROL PRODUCTS.

Chassieu (France), March 18, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Material Transfer Agreement with the DE SANGOSSE group. This partnership with an international player in crop protection, plant nutrition and pest control aims at extending the performance evaluation of biocontrol products containing the active substance of Amoeba: the amoeba lysate *Willaertia magna C2c Maky*.

As the French leader in biosolutions, the DE SANGOSSE group is particularly interested in substances of natural origin and wants to test products containing the active substance of Amoéba as a fungicide.

The purpose of this research partnership is the delivery by Amoéba of experimental products containing the amoeba lysate *Willaertia magna C2c Maky*. In return, the DE SANGOSSE group will carry out its own field trials in order to evaluate the performance of these products in preventing essential diseases of cereals, potatoes, apples and beet.

Amoéba and DE SANGOSSE are thus beginning a targeted research phase which, if successful, could promote the commercial development of Amoéba's biocontrol solutions.

"In line with our BioSolutions strategy, DE SANGOSSE wanted to test Amoéba's innovation in 2020 in order to measure its technical and economic potential. On this basis, DE SANGOSSE could envisage the continued development of this project with Amoéba in the years to come" indicates Nicolas Fillon, Managing Director of DE SANGOSSE.

"A closer relationship with the major players in crop protection is part of Amoéba's development strategy for its biocontrol activity. These trials have a significant potential for the company to add value and are an essential step towards a possible commercial partnership," explains Fabrice Plasson, CEO of Amoéba

Amoéba recalls that the company is still in the testing phase for its biocide and biocontrol applications and does not currently market any product.

About DE SANGOSSE

DE SANGOSSE (Agen - France) is a French company that innovates, manufactures and markets products on the Plant Protection and Nutrition and Pest Control markets. The group's mission is to provide high-performance technical solutions and a high level of expertise to its customers in its strategic fields of activity. The DE SANGOSSE range of

products is regularly enriched by new innovations thanks to significant investments allocated to Research and Development. The group's approach is to promote modern, productive and environmentally friendly agriculture. DE SANGOSSE has a turnover of 280 M€ and employs 850 people worldwide. The majority of DE SANGOSSE's equity is held by its employees, which guarantees its independence and ensures a long-term vision of the business project.

Contacts:

Nicolas FILLON
Directeur Général
06 46 23 70 79
fillonn@desangosse.com

Christophe ZUGAJ
Responsable Communication
06 16 54 92 47
zugajc@desangosse.com



About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): *Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

(2): *Sources combined by Amoéba from water treaters, Freedomia, Eurostat et MarketsandMarkets*

(3): *BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017*

(4): *Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

Contacts:

Amoéba

Valérie FILIATRE
Directeur Général Adjoint
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Calyptus

Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
01 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOÉBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOÉBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOÉBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 25, 2019 under number D19-0383 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOÉBA or not currently considered material by AMOÉBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOÉBA to be materially different from such forward-looking statements.

